Position in JANX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,052,674
-$1,365,748 QoQ
Shares Held
75,732
-56.8% QoQ
Ownership
0.124%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Rafferty Asset Management, LLC holds $408,627,656 across 136 Biotechnology names. JANX ranks #97 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
54,572 | $24,368,580 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
29,589 | $22,861,644 | |
| 3 | INSM |
INSMED Inc
|
116,069 | $18,979,602 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
50,553 | $16,726,471 | |
| 5 | APLS |
Apellis Pharmaceuticals, Inc.
|
180,471 | $7,260,348 | |
| 6 | MRNA |
Moderna, Inc.
|
114,194 | $5,801,055 | |
| 7 | INCY |
Incyte Corp
|
60,565 | $5,700,377 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
10,452 | $5,471,308 |
All Filings in JANX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,052,674 | 75,732 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,418,422 | 175,248 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,862,230 | 76,196 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,084,059 | 46,929 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,519,533 | 56,279 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $2,793,074 | 52,168 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $2,984,296 | 65,690 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $3,235,834 | 77,246 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||